Back to top
more

Akero Therapeutics (AKRO)

(Delayed Data from NSDQ)

$29.76 USD

29.76
720,241

-1.21 (-3.91%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $29.00 -0.76 (-2.55%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Immunome (IMNM) Surges on Merger Agreement With Morphimmune

by Zacks Equity Research

Immunome's (IMNM) shares rise following its announcement to merge with Morphimmune. The synergy will help strengthen the development of oncology therapies.

Liquidia (LQDA) Up on Deal With Pharmosa to Co-Develop PH Drug

by Zacks Equity Research

Liquidia (LQDA) signs an exclusive licensing agreement with Pharmosa to jointly develop and commercialize PAH and PH-ILD treatment candidate, L606, in North America. Shares of the company rise 11%.

Esperion (ESPR) to Expand Nilemdo and Nustendi Label in Europe

by Zacks Equity Research

Esperion (ESPR) files type II(a) variation application for expanded use of Nilemdo and Nustendi in Europe to reduce cardiovascular risk.

Axsome (AXSM) Down on Public Offering of Common Stock

by Zacks Equity Research

Axsome (AXSM) is set to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines.

Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7%

by Zacks Equity Research

Reata's (RETA) prior approval supplement application to update the drug substance specification for Skyclarys gets FDA's nod. Shares of the company gain 7% on Wednesday in response.

Amicus (FOLD) Gets Approval in Europe for Pompe Disease Drug

by Zacks Equity Research

Amicus (FOLD) receives approval for Opfolda (miglustat) from the European Commission to treat the adult late-onset Pompe disease.

Regeneron (REGN) Gets CRL for Aflibercept 8 mg Drug, Shares Fall

by Zacks Equity Research

Regeneron (REGN) receives a completed response letter for the application seeking approval of aflibercept 8 mg for treating several retinopathic indications. The stock falls 9% following the news.

Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint

by Zacks Equity Research

Agios' (AGIO) mid-stage, label expansion study of mitapivat meets its primary endpoint. The data from the study supports AGIO's decision to proceed with the phase III portion of the investigation.

Walgreens Boots' (WBA) Q3 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Walgreens Boots' (WBA) U.S. Healthcare business expands, owing to key contract wins, continued partnership growth and a strong focus on execution.

Walgreens (WBA) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strategic executions on the United States and the international front is likely to drive Walgreens' (WBA) Q3 revenues.

AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval

by Zacks Equity Research

AbbVie (ABBV) receives a positive recommendation from the European Union's medicinal products committee for the approval of its migraine treatment candidate, atogepant.

Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data

by Zacks Equity Research

Novo Nordisk (NVO) announces encouraging new data from its late-stage ONWARDS 1 and 3 studies on once-weekly basal insulin icodec against once-daily comparators at 52 and 26 weeks, respectively.

Amylyx (AMLX) Down on Negative CHMP Opinion for ALS candidate

by Zacks Equity Research

Amylyx's (AMLX) shares plunge on getting a negative opinion from the Committee for Medicinal Products for Human Use for the marketing authorization of AMX0035, used to treat amyotrophic lateral sclerosis.

Recent Price Trend in Akero Therapeutics, Inc. (AKRO) is Your Friend, Here's Why

by Zacks Equity Research

Akero Therapeutics, Inc. (AKRO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Pfizer's (PFE) Litfulo Receives FDA Nod for Alopecia Areata

by Zacks Equity Research

Pfizer's (PFE) Litfulo becomes the first kinase inhibitor approved for treating severe alopecia areata in adolescents, following FDA's approval.

Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate

by Zacks Equity Research

Pieris' (PIRS) shares nosedive as its partner decides to discontinue a phase IIa study evaluating elarekibep for treating asthma, based on non-clinical safety data from a toxicology study.

Aeglea (AGLE) Soars 329% on Acquiring Spyre Therapeutics

by Zacks Equity Research

Aeglea's (AGLE) shares surge as it acquires Spyre Therapeutics, a private company that focuses on developing antibody therapeutics for inflammatory bowel disease.

Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal

by Zacks Equity Research

Horizon (HZNP) announces positive top-line results from its phase III study evaluating Tepezza for treating Thyroid Eye Disease with high disease activity in Japan.

uniQure (QURE) Falls on Mixed Huntington's Disease Study Results

by Zacks Equity Research

uniQure (QURE) stock declines after the company announces mixed results from its biomarkers analysis in the early-to-mid-stage study of AMT-130 in Huntington's disease.

Amgen's (AMGN) Blincyto sBLA Gets FDA Nod in Treating Leukemia

by Zacks Equity Research

Amgen (AMGN) announces full approval of its sBLA for Blincyto as an immune-oncology therapy for treating adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia.

Alderya (ALDX) Stock Declines on Getting CRL for PVRL Candidate

by Zacks Equity Research

Alderya's (ALDX) shares decline on receiving a complete response letter for an investigational candidate, ADX-2191, treating primary vitreoretinal lymphoma.

Denali (DNLI) Provides Update on Hunter Syndrome Study

by Zacks Equity Research

Denali's (DNLI) early-to-mid-stage study of DNL310 shows a robust reduction in neurofilament light levels for patients with MPS II (Hunter syndrome).

Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug

by Zacks Equity Research

Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.

Merck's (MRK) Gastric Cancer Study Fails to Meet a Primary Goal

by Zacks Equity Research

Merck's (MRK) late-stage study evaluating Keytruda in advanced gastric cancer fails to meet one of the primary endpoints.

Verve (VERV) Up 9.9% in a Week on Collaboration With Eli Lilly

by Zacks Equity Research

Verve's (VERV) shares rise on collaboration with Eli Lilly to develop gene editing treatment for cardiovascular disease.